Real-world evolution of first-line ALK-positive NSCLC management in Spain. (PubMed, Clin Transl Oncol) - Oct 7, 2026 - "The management of ALK-positive NSCLC in Spain has evolved following the pricing and reimbursement of lorlatinib for first-line treatment in Spain, with changes in treatment selection and molecular testing practices observed in routine clinical settings."
Journal • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|
|
Antonio José Montes; Elisabet Garcia; Gerardo Villa; Jon Zugazagoitia; Virginia Calvo
|